Navigation Links
Agendia Appoints VP of Business Development
Date:2/11/2009

HUNTINGTON BEACH, California and AMSTERDAM, The Netherlands, February 11 /PRNewswire/ -- Agendia, a world leader in molecular cancer diagnostics, today announced the appointment of Alan B. Carter as the company's new Vice President of Global Business Development.

"As we continue to grow as a global company, Alan's appointment furthers one of our primary aims," commented Dr. Bernhard Sixt, Ph.D., President and Chief Executive Officer. "His extensive business development expertise will strengthen our ongoing programs and pipeline projects and also allows us to capitalize on our genomics platform in close collaboration with biotechnology and pharmaceutical partners. With Alan's involvement, Agendia will continue to play a central role in making targeted therapies one of the cornerstones of personalized medicine."

Mr. Carter brings 25 years of business development, sales and marketing experience from a number of top tier life sciences companies such as BioTrove, Celera, Applied Biosystems and Perkin Elmer. At Agendia, Mr. Carter will assume responsibility for strategic business opportunities to build on the current success of Agendia's molecular diagnostics portfolio. This products suite includes MammaPrint(R), the only FDA approved test for rapidly and accurately diagnosing therapeutic options for breast cancer patients. Additionally, he will play an important role in forging Agendia's strategic alliances with pharmaceutical and biotech companies to accelerate the use of molecular diagnostics in drug development, companion diagnostics and safety testing programs.

About Agendia

Agendia is at the forefront of the personalized medicine revolution, striving to bring more effective, individualized treatments within reach of patients. Building on a cutting edge genomics platform for tumor gene expression profiling, the company's tests aim to help physicians more accurately tailor cancer treatments. The company markets four products, with several new genomic tests under development. In addition, Agendia collaborates with pharmaceutical companies to develop highly effective personalized drugs in the area of oncology. Agendia was awarded the 2008 North American Oncology Clinical Diagnostics Healthcare Innovation Award by Frost & Sullivan. Agendia is based in Huntington Beach, California, and in Amsterdam, The Netherlands.

For more information please visit http://www.agendia.com.


'/>"/>
SOURCE Agendia B.V.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Agendia BV Appoints Mr. Hessel Lindenbergh as Chairman of its Supervisory Board
2. Agendia Joins the Personalized Medicine Coalition (PMC)
3. Agendia Acquires Rights to the Discovery of a Major Drug Resistance Mechanism in Breast Cancer Potentially Leading to a Herceptin(R) Sensitivity Test
4. Agendia BV Announces That its Chief Research Officer Laura van t Veer has Received a 2007 Breast Cancer Research Foundation Award
5. Agendia BV Appoints Clinical and Scientific Advisory Board
6. Agendia and Agilent Announce Plans to Jointly Develop New Diagnostic Tests, Extend Supply Agreement
7. Agendias MammaPrint(R) Receives Prestigious Award From Dutch Innovation Platform
8. Agendia and Ferrer Announce Exclusive Agreement for Sales of Cancer Diagnostic Services in Four Major European Markets
9. Agendia Appoints New Chief Financial Officer
10. Agendias Breast Cancer Test MammaPrint(R) Standard of Care at Netherlands Cancer Institute - AVL
11. BioVex Appoints Dr. Thaddeus Pullano as VP, Quality Assurance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2016)... , ... April 26, 2016 , ... This unique "Fertility ... and will offer attendees an opportunity to get the lowdown on female fertility and ... cocktails and appetizers, Dr. Jesse Hade, of Boston IVF - The Arizona Center, will ...
(Date:4/26/2016)... ... April 26, 2016 , ... Seattle based non-profit, The Institute ... 1Plus12 Corporation. The grant will be used to further the scientific research goals ... website http://www.ivsci.org , In accounting the grant to the IVS, Mr. ...
(Date:4/26/2016)... ... April 26, 2016 , ... uBiome, the leading microbial genomics company, welcomes Neil ... Advisory Board. Prior to co-founding Plum in 2007, Neil Grimmer was Vice President of ... A renowned, innovative designer of ideas, products, and brands, Grimmer has been at the ...
(Date:4/26/2016)... genae, a Contract Research Organization ... today the appointment of Prof. Dr. Jörn Balzer to ... will include all clinical, safety and risk management related ... and honored with the acceptance of Prof. Balzer to ... at genae. "Prof. Balzer,s impressive and extensive background make ...
Breaking Biology Technology:
(Date:4/28/2016)... and BANGALORE, India , April ... EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... today announced a global partnership that will provide ... to use mobile banking and payment services.      ... a key innovation area for financial services, but it also ...
(Date:4/28/2016)... , April 28, 2016 First quarter ... (139.9), up 966% compared with the first quarter of 2015 ... totaled SEK 589.1 M (loss: 18.8) and the operating margin was ... (loss: 0.32) Cash flow from operations was SEK 249.9 ... 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. The ...
(Date:4/26/2016)... LONDON , April 26, 2016 ... EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... a partnership to integrate the Onegini mobile security ... (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ) The ... enhanced security to access and transact across channels. ...
Breaking Biology News(10 mins):